How are ATTR-CM drugs priced?
Attruby launched at ~$244,000 — below Vyndamax at ~$268,000 and far below Amvuttra at ~$476,000 — with analysts warning the silencer faces 'significant payer headwinds' at nearly double the stabiliser price.
All three approved drugs are expensive, but BridgeBio's Attruby has the lowest list price. BridgeBio launched Attruby at about $244,000 a year, below tafamidis at nearly $268,000 in 2024, while Alnylam priced Amvuttra for ATTR-CM at about $476,000 a year, nearly double its stabiliser rivals, prompting analysts to warn of "significant payer headwinds." BridgeBio's CEO describes Attruby as "the lowest-priced product with the best data at 30 months", and in August 2026 BridgeBio agreed with the US government to keep offering Attruby through Medicare Part D. BridgeBio's Attruby has also been shown to be the most effective: its trial showed benefits within about three months, a real-world study found a 34% lower risk of clinical worsening than with tafamidis, and it reports kidney-protection data and a 41% reduction in outpatient worsening heart failure.